HER2陰性乳癌治療薬の世界市場予測および分析...市場調査レポートについてご紹介

【英文タイトル】PharmaPoint: HER2-Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2023

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 26
2.1 Catalyst 26
2.2 Related Reports 27
2.3 Upcoming Related Reports 27
3 Disease Overview 28
3.1 Etiology and Pathophysiology 28
3.1.1 Etiology 28
3.1.2 Pathophysiology 29
3.1.3 Basic Breast Anatomy 30
3.2 Disease Classification/Staging Systems 31
3.3 Symptoms 33
3.4 Prognosis 33
3.5 Quality of Life 34
4 Epidemiology 37
4.1 Disease Background 37
4.2 Risk Factors and Comorbidities 37
4.2.1 A family history of breast cancer and BRCA1/2 gene mutations significantly increase the breast cancer risk 39
4.2.2 Reproductive hormonal factors influence the risk of breast cancer 39
4.2.3 Modifiable lifestyle-related factors increase the risk of mortality in breast cancer patients 41
4.2.4 Screening programs have been shown to reduce breast cancer mortality, although the benefits need to be carefully weighed against the risks 43
4.3 Global Trends 46
4.3.1 Incidence 46
4.3.2 Prevalence and Survival 52
4.4 Forecast Methodology 56
4.4.1 Sources Used 58
4.4.2 Sources Not Used 62
4.4.3 Forecast Assumptions and Methods 63
4.5 Epidemiological Forecast for Breast Cancer (2013-2023) – Diagnosed Incident Cases 66
4.5.1 Diagnosed Incident Cases of Breast Cancer 66
4.5.2 Diagnosed Incident Cases of Breast Cancer by Age 68
4.5.3 Diagnosed Incident Cases of Breast Cancer by Menopausal Status 70
4.5.4 Diagnosed Incident Cases of Breast Cancer Segmented by Stage at Diagnosis 72
4.5.5 Age-Standardized Diagnosed Incidence Rate of Breast Cancer 73
4.6 Epidemiological Forecast for Breast Cancer (2013-2023) — Diagnosed Prevalent Cases 74
4.6.1 Five-Year Diagnosed Prevalent Cases of Breast Cancer 74
4.6.2 Five-Year Diagnosed Prevalent Cases by Menopausal Status 76
4.6.3 Five-Year Diagnosed Prevalent Cases by Hormone Receptor Subtypes 77
4.7 Discussion 79
4.7.1 Epidemiological Forecast Insight 79
4.7.2 Limitations of the Analysis 81
4.7.3 Strengths of the Analysis 82
5 Disease Management 84
5.1 Diagnosis and Treatment Overview 84
5.1.1 Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB) 84
5.1.2 Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIC) 86
5.1.3 Treatment Guidelines and Leading Prescribed Drugs 90
5.2 US 91
5.2.1 Diagnosis 91
5.2.2 Clinical Practice 92
5.3 France 95
5.3.1 Diagnosis 95
5.3.2 Clinical Practice 96
5.4 Germany 99
5.4.1 Diagnosis 99
5.4.2 Clinical Practice 100
5.5 Italy 103
5.5.1 Diagnosis 103
5.5.2 Clinical Practice 104
5.6 Spain 106
5.6.1 Diagnosis 106
5.6.2 Clinical Practice 107
5.7 UK 110
5.7.1 Diagnosis 110
5.7.2 Clinical Practice 111
5.8 Japan 114
5.8.1 Diagnosis 114
5.8.2 Clinical Practice 115
5.9 China 117
5.9.1 Diagnosis 117
5.9.2 Clinical Practice 119
6 Competitive Assessment 122
6.1 Overview 122
6.2 Product Profiles (Branded Therapies) 123
6.2.1 Abraxane (nab-paclitaxel) 123
6.2.2 Afinitor (everolimus) 128
6.2.3 Avastin (bevacizumab) 133
6.2.4 Doxil/Caelyx (pegylated liposomal doxorubicin) 137
6.2.5 Halaven (eribulin mesylate) 142
6.2.6 Ixempra (ixabepilone) 145
6.2.7 Xeloda (capecitabine) 148
6.3 Product Profiles (Hormonal Agents) 151
6.3.1 Tamoxifen 151
6.3.2 Faslodex (fulvestrant) 151
6.3.3 Aromatase Inhibitors 152
7 Unmet Need and Opportunity 156
7.1 Overview 156
7.1.1 Defined treatment plan for BRCA mutation-positive patients and prevention of prophylactic surgeries 158
7.1.2 Specific treatment options for TNBC patients 160
7.1.3 Prevention of brain metastasis 161
7.1.4 Neoadjuvant therapy that can downstage tumors 163
7.1.5 For HR+patients, reduced resistance to hormonal agents 164
7.1.6 Improved convenience of administration of hormonal agents 166
8 Pipeline Assessment 168
8.1 Overview 168
8.1.1 Abemaciclib (LY2835219) 169
8.1.2 Buparlisib (BKM- 120) 175
8.1.3 Javlor (vinflunine) 181
8.1.4 LEE011 185
8.1.5 NeuVax (nelipepimut-S/E75) 190
8.1.6 Niraparib (MK4827) 195
8.1.7 NKTR- 102 (etirinotecan pegol) 200
8.1.8 Lynparza (olaparib) 204
8.1.9 Palbociclib (PD-0332991) 209
8.1.10 Talazoparib (BMN 673) 215
8.1.11 Veliparib (ABT-888) 219
8.2 Promising Drugs in Clinical Development 224
8.2.1 PD-/PD-L 1 Immunotherapies 225
9 Current and Future Players 227
9.1 Overview 227
9.2 Trends in Corporate Strategy 229
9.3 Company Profiles 232
9.3.1 AstraZeneca 232
9.3.2 Bristol-Myers Squibb 233
9.3.3 Eli Lilly 235
9.3.4 Pfizer 236
9.3.5 Novartis/GlaxoSmithKline 239
10 Market Outlook 241
10.1 Global Markets 241
10.1.1 Forecast 241
10.1.2 Drivers and Barriers – Global Issues 247
10.2 US 249
10.2.1 Forecast 249
10.2.2 Key Events 252
10.2.3 Drivers and Barriers 253
10.3 France 255
10.3.1 Forecast 255
10.3.2 Key Events 258
10.3.3 Drivers and Barriers 259
10.4 Germany 260
10.4.1 Forecast 260
10.4.2 Key Events 264
10.4.3 Drivers and Barriers 265
10.5 Italy 266
10.5.1 Forecast 266
10.5.2 Key Events 270
10.5.3 Drivers and Barriers 271
10.6 Spain 272
10.6.1 Forecast 272
10.6.2 Key Events 275
10.6.3 Drivers and Barriers 276
10.7 UK 277
10.7.1 Forecast 277
10.7.2 Key Events 281
10.7.3 Drivers and Barriers 282
10.8 Japan 284
10.8.1 Forecast 284
10.8.2 Key Events 287
10.8.3 Drivers and Barriers 288
10.9 China 289
10.9.1 Forecast 289
10.9.2 Key Events 292
10.9.3 Drivers and Barriers 292
11 Appendix 294
11.1 Bibliography 294
11.2 Abbreviations 321
11.3 Methodology 329
11.4 Forecasting Methodology 329
11.4.1 Diagnosed HER2-Negative Breast Cancer Patients 329
11.4.2 Percentage of Drug-Treated Patients 330
11.4.3 Drugs Included in Each Therapeutic Class 330
11.4.4 Launch and Patent Expiry Dates 331
11.4.5 General Pricing Assumptions 332
11.4.6 Individual Drug Assumptions 334
11.4.7 Generic Erosion 342
11.4.8 Pricing of Pipeline Agents 342
11.5 Primary Research – KOLs Interviewed for This Report 353
11.6 Primary Research – High-Prescriber Survey 355
11.7 About the Authors 356
11.7.1 Analyst 356
11.7.2 Director of Oncology 356
11.7.3 Epidemiologist 357
11.7.4 Director of Epidemiology 357
11.7.5 Global Head of Healthcare 358
11.8 About GlobalData 359
11.9 Disclaimer 359


【レポート販売概要】

■ タイトル:HER2陰性乳癌治療薬の世界市場予測および分析
■ 英文:PharmaPoint: HER2-Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2023
■ 発行日:2015年1月31日
■ 調査会社:GlobalData
■ 商品コード:GDHC92PIDR
■ 調査対象地域:グローバル
  • ELISA(エライサ)検査の世界市場2015-2019
    About ELISA test ELISA test is one of the most common laboratory technologies that is used for measuring the concentration of analytes such as antigens and antibodies in solution. ELISA test uses various types of enzymes such as carbonic anhydrase, glucose oxidase, and alkaline phosphatases and the result is detected by photometry or fluorometry. ELISA is used as a screening test in the treatment …
  • 世界のウルソデオキシコール酸市場2015
    The Global Ursodeoxycholic Acid Industry Report 2015 is a professional and in-depth study on the current state of the Ursodeoxycholic Acid industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Ursodeoxycholic Acid market analysis is provided for the international markets including development trends, co …
  • 航空交通管制(ATC)装置の世界市場:通信装置、航法装置、監視装置
    About the Air Traffic Control Equipment Market Due to the robust growth in the aviation industry, safety has become the priority for airports and airline operators. ATC equipment plays a vital role in the safe operations of carriers, as it provides communications, navigation, and surveillance (CNS) facilities using different equipment for air traffic management (ATM). The primary job of an ATC equ …
  • 心血管系超音波検査システムの世界市場予測2021:経胸壁心エコー図、経食道心エコー図、負荷心エコー図
    The cardiovascular ultrasound system market is projected to reach USD 1.66 Billion by 2021 from USD 1.27 Billion in 2016, growing at a CAGR of 5.4% during the forecast period. Increasing incidence of cardiovascular diseases, technological advancements, and advantages of echocardiography over invasive cardiac diagnostic procedures is driving the growth of this market. However, insufficient reimburs …
  • Questerre Energy Corporation:石油・ガスの開発・生産動向及びコスト分析- Q3, 2013
    Questerre Energy Corporation Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Questerre Energy Corporation Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an es …
  • エピタキシー成長の世界市場2016-2020
    About Epitaxy Deposition Epitaxy is a method used to lay or grow a single crystalline film or layer over a crystalline-based semiconductor substrate or surface. The deposited substance must have a definite acclimatization with regard to the crystal-based semiconductor substrate. Chip manufacturers use either vapor- or molten-based foundations to develop such epitaxial overlayers. The two methods t …
  • 債権回収ソフトウェアの世界市場予測(~2024年)
    Growing demand for automation and self-service payment models to improve the collection process are expected to drive the growth of the debt collection software marketThe global debt collection software market size is expected to grow from an estimated value of USD 2.9 billion in 2019 to USD 4.6 billion by 2024, at a CAGR of 9.6% during the forecast period. The debt collection software industry is …
  • ヘルスケアサイバーセキュリティの世界市場展望2017-20276
    According to Stratistics MRC, the Global Healthcare Cyber Security Market is accounted for $6.88 billion in 2017 and is expected to reach $36.88 billion by 2026 growing at a CAGR of 20.5% during the forecast period. Increasing demand for cloud services, and rising cases of healthcare cyber-attacks are the key driving factors for the market growth. However, shortage of trained professionals is hind …
  • 医療廃棄物管理に関する世界市場動向と予測
    The growing demand of the pharmaceutical industry and aging population drives the medical waste management market. The total market revenue, in terms of geography, is expected to reach $10,327.0 million, growing at a CAGR of 4.9% from 2013 to 2018. The Americas dominates the market with $3,100.0 million in 2013, and is expected to reach $4,040.0 million by 2018, at a CAGR of 5.4%. This is followed …
  • 世界におけるエピジェネティクスの研究開発、治療薬、診断製品市場
    Epigenetics market – new analysis showing you technological trends and sales forecasts Do you want to find sales potentials of epigenetic technologies, diagnostics and medicines? Now get the latest analysis for that industry. There you explore developments (R&D), results, opportunities, trends and revenue forecasts. Visiongain’s updated report shows you what’s possible for those drugs, diagnostic …
  • 世界の過ホウ酸塩市場2015
    The Global Perborates Industry Report 2015 is a professional and in-depth study on the current state of the Perborates industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Perborates market analysis is provided for the international markets including development trends, competitive landscape analysis, a …
  • クリプトコッカス症(Cryptococcosis):治療薬開発パイプライン動向(2015年上半期版)
    Cryptococcosis - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Cryptococcosis - Pipeline Review, H1 2015’, provides an overview of the Cryptococcosis’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cryptococcosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action ( …
  • 世界のデジタルメディア市場:モバイル及びオンラインエンターテインメント動向
    Digital developments continue to direct the future of entertainmentThe growth of digital platforms and services has resulted in the global media industry changing irrevocably. What the shareholders in the traditional media sectors often fail to understand is that the game is no longer directed at building up big revenues upon which to build future business models. Instead the focus is now on build …
  • コネクティッド・カー市場動向及び予測(2014-2019)
    The automobile industry is very competitive. The profitability on cars is slim with margins in the US as low as two percent on a new car. The large motor companies can make money by self-financing consumer deals. Dealerships hope to make money by promoting repair service packages, and offering extended warranties. The connected car is considered a gift because it is a new revenue stream, has a bet …
  • ヨーロッパ主要国の睡眠時無呼吸診断装置市場
    EU5 Sleep Apnea Diagnostic Systems Market Outlook to 2021 Summary GlobalData’s new report, "EU5 Sleep Apnea Diagnostic Systems Market Outlook to 2021", provides key market data on the EU5 Sleep Apnea Diagnostic Systems market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market segments Fixed Polysomnography Systems and Port …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。